Clinical trial
Non-interventional Observational Post-authorization Study to Assess Clinical and Patient Reported Outcomes With Nab-paclitaxel in Combination With Gemcitabine in Routine Clinical Practice Treating Pancreatic Cancer (TRUST)
NCT02670746 is registered in ClinicalTrials.gov with Celgene as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Non-interventional Observational Post-authorization Study to Assess Clinical and Patient Reported Outcomes With Nab-paclitaxel in Combination With Gemcitabine in Routine Clinical Practice Treating Pancreatic Cancer (TRUST)
- Lead sponsor
- Celgene
- Phase
- Observational
- Overall status
- Terminated
- Start date
- October 1, 2015
- Completion date
- November 28, 2017
- Enrollment
- 44 (actual)
- Sites
- 18
Conditions
As the registry lists them; a condition with its own page is linked.